Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2009

Targeting colorectal cancer with anti-epidermal growth factor
receptor antibodies: focus on panitumumab
Kerry J. Williams
Washington University School of Medicine in St. Louis

A. Craig Lockhart
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Part of the Medicine and Health Sciences Commons

Recommended Citation
Williams, Kerry J. and Lockhart, A. Craig, ,"Targeting colorectal cancer with anti-epidermal growth factor
receptor antibodies: focus on panitumumab." OncoTargets and Therapy. 18,2. 161-170. (2009).
https://digitalcommons.wustl.edu/open_access_pubs/315

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

OncoTargets and Therapy

Dovepress
open access to scientific and medical research

review

Open Access Full Text Article

Targeting colorectal cancer with anti-epidermal
growth factor receptor antibodies: focus
on panitumumab
This article was published in the following Dove Press journal:
OncoTargets and Therapy
26 June 2009
Number of times this article has been viewed

Kerry J Williams
A Craig Lockhart
Department of Medicine, Division
of Medical Oncology, Washington
University School of Medicine
St. Louis, MO, USA

Abstract: The tumor biology targeted therapies have improved outcomes in colorectal cancer
(CRC). The epidermal growth factor receptor (EGFR) inhibitors represent one of these
successful strategies. EGFR is frequently overexpressed in CRCs and associated with a malignant phenotype. Two EGFR inhibitors have shown efficacy in metastatic CRC, cetuximab
and panitumumab. Cetuximab is a human–mouse chimeric monoclonal antibody that binds to
the extracellular domain of the EGF-receptor. Similarly, panitumumab is a fully humanized
monoclonal IgG2 antibody, directed against EGFR. Being fully humanized, panitumumab does
not contain mouse protein reducing the risk of hypersensitivity. In a pivotal clinical trial, panitumumab was well tolerated and effective, demonstrating an objective response rate of 10% vs
best supportive care (ORR = 0%; P  0.0001). Panitumumab was approved for the treatment of
mCRC by the FDA in 2006. Studies combining panitumumab with cytotoxic chemotherapy and
other targeted therapies have been completed while others are ongoing to further evaluate the
clinical utility of this agent. Recently it has been demonstrated that mutations in KRAS predict
the efficacy of panitumumab and cetuximab, limiting their use to CRC patients with wild-type
KRAS, and moving the clinical field towards personalized cancer care.
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World-wide, colorectal cancer is the third most common cancer in both men and women.
In 2008, it is estimated that 148,810 cases of colorectal cancer will be diagnosed and
49,960 people will die from this disease.1 Despite the prevalence of this disease, the
overall incidence and death rates have declined over the last 20 years, suggesting
improvements in early detection and treatments. Unfortunately, approximately 20%
of patients will have metastatic disease at the time of presentation. Chemotherapeutic
agents that have been US Food and Drug Administration (FDA) approved for the use
in metastatic colorectal cancer (mCRC) include 5-fluorouracil (5-FU), capecitabine,
irinotecan and oxaliplatin. In recent clinical trials, the median overall survival for
patients treated with irinotecan and oxaliplatin-based regimens approaches 20 months,
an improvement in comparison to the 12 month median survival prior to the approval
of these agents.2,3
As we learn more about the biology of cancer and its pathways, potential targets for
therapy have been identified. These novel biologic agents are well poised to potentially
advance the progress of the treatment of mCRC. Bevacizumab, an anti-angiogenic agent,
is an example of a targeted agent improving outcomes in mCRC. The addition of bevacizumab to a combination chemotherapy regimen of irinotecan, 5-FU and leucovorin (IFL)

OncoTargets and Therapy 2009:2 161–170
161
© 2009 Williams and Lockhart, publisher and licensee Dove Medical Press Ltd. This is an Open Access
article which permits unrestricted noncommercial use, provided the original work is properly cited.

Dovepress

Williams and Lockhart

increased the median duration of survival from 15.6 months
(IFL) to 20.3 months (bevacizumab plus IFL; P  0.001).4
The epidermal growth factor receptor (EGFR) has been
shown to be frequently overexpressed in CRC5,6 and has been
associated with a malignant phenotype.6–9 Multiple clinical
trials have been performed and are currently ongoing to
evaluate EGFR-targeted agents in CRC. Thus far, two EGFR
inhibitors have shown efficacy in mCRC, namely cetuximab
(Erbitux®; ImClone Systems, Brachburg, NJ, USA) and
panitumumab (Vectibix®; Amgen, Thousand Oaks, CA,
USA). Cetuximab, a human–mouse chimeric monoclonal
antibody that binds specifically to the extracellular domain of
the EGF-receptor results in inhibition of cellular growth, and
angiogenesis and promotes apoptosis. Significant improvement in overall response rates were demonstrated in patients
with colorectal cancer, refractory to irinotecan, who received
cetuximab in combination with irinotecan (overall response
rate [ORR] 22.9%) vs cetuximab alone (ORR 10.8%).10 There
was a trend in improved overall survival for the cetuximab
in combination with irinotecan arm vs the cetuximab alone
arm (8.6 months vs 6.9 months, P = 0.48). The results of this
study led to the approval of cetuximab for the treatment of
patients with mCRC.
Panitumumab is a fully humanized monoclonal antibody to EGFR that has shown encouraging activity and
tolerability in heavily pretreated patients with MCRC. It
selectively targets the extracellular domain of the EGFR.
It was Food and Drug Administration (FDA) approved in
September 2006 and is currently indicated for the treatment
of mCRC in EGFR-expressing tumors that have progressed
following treatment with fluoropyrimidine-, oxaliplatin-,
and irinotecan-containing chemotherapy regimens. There
are also ongoing trials in first- and second-line settings. In
this review, we will discuss the EGFR signaling pathway,
focusing on panitumumab and its pharmacology and efficacy
in colorectal cancer. We will also review the toxicities related
to panitumumab as well as provide insight into potential
biomarkers of response, including k-ras and BRAF.

EGFR signaling and its role
in colorectal cancer
EGFR is a transmembrane tyrosine kinase, belonging to a
family of human epidermal growth factor receptors (HER1).
Other members within this family include HER2 (ERBB2),
HER3 (ERBB3) and HER4 (ERBB4). All members within
this family, with the exception of HER2, which has no
apparent ligand, have an extracellular ligand-binding domain, a
transmembrane lipophilic segment and an intracellular domain
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with tyrosine kinase activity. In response to ligand binding by
the epidermal growth factor and transforming growth factor α
(TGF-α), the EGFR homodimerizes and/or forms heterodimers
with other members of the ERBB family (especially HER2).
This then leads to the activation of EGFR tyrosine kinases
through phosphorylation. This phosphorylation results in the
activation of several intracellular second-messenger signal
transduction pathways, such as the Janus kinase-Signal transducer an activator of transcription signaling, the phosphatidylinositol-3-kinase and the protein-serine/threonine kinase
Akt signal, and the Ras-Raf-MAP-kinase signal, which further
activates the mitogen-activated phosphorylation protein
kinases. Ultimately, the signaling of the pathways leads to
increased cell proliferation, division, survival, invasion, adhesion and DNA repair in malignant and nonmalignant cells. If
these pathways are dysregulated, such as in the case of EGFR
overexpression, alterations in cellular growth, survival, angiogenesis and metastases may occur.11–18
The proposed development of colorectal cancer evolves
from the progressive accumulation of genetic and epigenetic
alterations resulting in the transformation of normal colonic
mucosa to invasive adenocarcinoma.19 EGFR has been implicated in the initiation of colorectal tumors and has also been
noted to be frequently overexpressed in CRC.5,20 The prognostic significance of EGFR in CRC remains unclear.6,20

Panitumumab pharmacology
and pharmacokinetics
Panitumumab (ABX-EGF, E.7.6.3, Vectibix®), is a highaffinity, fully humanized monoclonal IgG 2 antibody,
directed against EGFR, generated in XenoMouse® (Abjenix,
Fremont, CA; transgenic mouse capable of producing human
antibodies). It is produced by immunizing a XenoMouse
strain of mice with human cervical epidermal carcinoma cell
line A431, a cell line known for its abundance of EGFR on the
cell surface.21,22 Unlike chimeric antibodies, fully humanized
monoclonal antibodies do not contain any amount of foreign
elements (ie, mouse protein) and thus do not generate human
antimouse antibodies. This reduces this risk of hypersensitivity reactions and thus, represents a theoretical clinical
advantage over previously developed chimeric antibodies.
The mechanism of action of panitumumab involves binding
of panitumuab to the EGFR with inhibition of ligand binding
of EGFR. It is rapidly internalized but not degraded internally.
The binding of panitumumab to EGFR results in downregulation of cell-surface EGFR by internalization of the receptor,
interruption of the intracellular signaling EGFR resulting
in apoptosis and initiation of cell-cycle arrest, inhibition of
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angiogenesis and possible inhibition of differentiation of the
tumor cells. With panitumumab being an IgG2 isotype, it is
unlikely to produce an immunologic-mediated response. Thus,
antibody-dependant cellular cytotoxicity (ADCC) is not implicated in panitumumab’s mechanism of action.23,24
The recommended dose of panitumumab is 6 mg/kg
given over 60 minutes as an intravenous infusion once every
2 weeks (package insert Vectibix: Thousand Oaks, CA:
Amgen Inc, Sept 2006). According to the manufacturer,
available pharmacokinetic data do not indicate that sex, age,
ethnicity, mild-to-moderate renal or hepatic dysfunction or
EGFR membrane-staining intensity in tumor cells affect the
pharmacokinetic properties of panitumumab. Use of the drug
has not been evaluated in pediatric and pregnant patients.
There have also not been any formal pharmacokinetic studies
performed in patients with hepatic and/or renal dysfunction.

Phase I studies
Panitumumab was initially evaluated in a multicenter,
open-label, dose-escalating phase I trial, where 43 patients
with various solid tumor types; renal (n = 10), prostate
(n = 13), non-small-cell lung cancer (n = 7), pancreatic (n =
3), esophageal (n = 3) and CRC (n = 7), received 4 intravenous infusions of panitumumab once weekly for up to 1
hour, at doses ranging from 0.01 mg/kg to 2.5 mg/kg. In all
the patients receiving the 2.0 to 2.5 mg/kg dose, a transient
dose-dependent skin rash was noted. No allergic reactions,
infusion reactions or serious adverse events were noted and
no human anti-human antibodies (HAHA) were found.25
Those patients with evidence of response or stable disease
were eligible to continue to receive treatment every other
week for 6 additional months or until disease progression.
Biologic activity was noted in patients even at the lowest
doses. One patient with esophageal cancer treated with the
lowest dose had stable disease (SD) for 7 months. A partial
response (PR) of 10 months duration was noted in one patient
with colorectal cancer treated with the 2.5 mg/kg dose.
An additional 50 patients were treated on the above study
and the updated results were presented by Weiner et al at the
ASCO 2005 meeting and has been subsequently published.26
Sequential cohorts were enrolled to receive four infusions
of panitumumab as a single-agent. There were different
dose levels ranging from 0.01 mg/kg to 5.0 mg/kg once
per week, 6.0 mg/kg every 2 weeks and 9.0 mg/kg every
3 weeks. A total of 96 patients were enrolled and treated
(CRC, n = 39, lung, n = 14, pancreatic, n = 21, renal, n = 15,
esophageal, n = 3 and anal cancer, n = 1). 10% of the patients
experienced Grade 3 or 4 toxicities, with Grade 3 skin rash
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being the most common adverse event noted (7%). Dose
escalation to 9.0 mg/kg every 3 weeks was achieved and no
maximal tolerated dose was reached. Pharmacokinetics were
consistent and predictable over the range of dosing, with low
intra-patient and inter-patient variablility. The minimal serum
panitumumab concentrations (Ctrough) were similar among
all the dose levels, with steady-state reached after approximately 6 weeks for all dosing schedules. Thus, even though
the maximum tolerated dose was not reached, the authors
decided that increasing the dose beyond those tested, would
unlikely result in increased panitumumab activity. Five of
the 39 CRC patients (13%) achieved a partial response (PR)
with 9 of 39 CRC patients (23%) had stable disease.
Rowinsky et al27 performed a phase I study of panitumumab in previously treated patients with metastatic renal
cell carcinoma. The primary objectives of the study were to
evaluate toxicity, immunogenicity, pharmacokinetics as well
as pharmacodynamics. A total of 88 patients were enrolled
and treated with panitumumab. They were treated with panitumumab doses of 1.0, 1.5, 2.0 or 2.5 mg/kg weekly with no
loading dose. Major responses were seen in three patients
and two patients had minor responses. Forty four patients
had stable disease (50%) at their first assessment at 8 weeks.
The median progression-free survival was 100 days [95%
confidence interval (CI), 58 to 140 days]. The main toxicity
noted was an acneiform rash which was dose dependant,
with 68, 95, 87 and 100% of patients who received at least
3 doses of panitumumab at 1.0, 1.5, 2.0, and 2.5 mg/kg/week
respectively. The rash reached maximal intensity at weeks 3
and 5, and then continued to dissipate despite ongoing treatment. Other frequent toxicities noted were asthenia, unspecified pain and back pain.

Phase II studies
Panitumumab as single-agent in treatment
of metastatic colorectal cancer
A number of phase II studies have confirmed the clinical
activity of panitumumab as well as the safety as reported in
earlier clinical trials. In the pivotal phase II trial by Malik et al
148 heavily pretreated patients with metastatic CRC were
treated with panitumumab administered at 2.5 mg/kg/week
over 1 hour with no loading dose or premedications.28 Patients
were enrolled into two cohorts, depending on levels of EGFR
protein expression (as determined by immunohistochemistry).
All the enrolled patients had received prior treatment with
fluoropyrimidines, 96% had received irinotecan therapy and
49% had received prior oxaliplatin therapy. Patients were
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allowed to continue on panitumumab as long as it was
tolerated and there was clinical benefit.
The most common toxicities noted were rash and fatigue.
The rash typically appeared within 1 to 3 weeks of initiating therapy and persisted, without worsening throughout
therapy. Only 4 patients discontinued therapy due to rash. It
was classically described as a maculopapular acneiform rash,
appearing on the face and trunk. Only 1 patient had a grade 3
infusion reaction and no HAHA antibodies were detected in
the 107 patients tested.
Nine per cent (13) patients were found to have responded
after 8 weeks of therapy, with 29% of patients with SD. The
median duration of response was 5.2 months and median OS
of 9.4 months. No significant difference was noted when the
results were analyzed according to the two cohorts based on
EGFR protein expression.
As with other EGFR inhibitors, there was a trend in the
correlation between the severity of the rash and response. At
least 62% of the patients who developed a rash of grade 2 or
more had either PR or SD.
Another phase II trial was undertaken to evaluate the efficacy of panitumumab in patients with mCRC, having received
more than 2 lines of previous therapy and whose tumors
expressed EGFR in 10% or more of the cells. Panitumumab
was given at 6 mg/kg every 2 weeks until disease progression. By 16 weeks, 8% of patients had a PR, with 21%
having SD. The most common toxicities noted were rash
(96%), nail (30%) and eye (8%) reactions, diarrhea (27%)
and hypomagnesemia (12%). One patient developed a grade
3 hypersensitivity reaction but continued on with therapy
without further reactions. No HAHA were detected.29
Patients with metastatic CRC with low (1% to 9%) or no
(1%) expression of EGFR were evaluated in another phase II
trial.30 In the 89 patients available for efficacy analysis, partial
responses and tumor control rates ranged from 7% to 9%
and 37% to 42% respectively. This is comparable with the
responses seen in patients with EGFR-expressing tumors.
Among the 118 patients evaluable for toxicity analysis, 72%
developed rash, 69% with erythema, pruritus in 65% and
hypomagnesemia in 53%. Three patients developed infusion
reactions, with only one being a grade 3 reaction.

Preclinical studies have also demonstrated that panitumumab
may also have an additive antitumor effect when used in
combination with cytotoxic chemotherapy.
Panitumumab (given at 2.5 mg/kg/week) in combination
with IFL (Saltz regimen: irinotecan 125 mg/m2, leucovorin
20 mg/m2 and 5-FU 500 mg/m2 on days 1, 8, 15 and 22)
was evaluated in patients with metastatic colorectal cancer
as first-line therapy.31,32 The primary objectives of the study
were to evaluate both safety and efficacy. All patients were
required to have EGFR expression of 2+ or 3+ in 10% of
tumor cells by immunohistochemistry. The first 19 patients
received panitumumab in combination with IFL weekly
for 4 weeks of each 6-week treatment cycle. The protocol
was amended to include another regimen (based on data
from the first few patients and changing practice from
bolus to infusional 5-FU), FOLFIRI (irinotecan 180 mg/m2,
leucovorin 400 mg/m2 and 5-FU as a 400 mg/m2 bolus
followed by 2.4 to 3 g/m2 over 46 hours).
Diarrhea was the most common noncutaneous toxicity
noted in the 19 patients that received panitumumab and IFL.
Skin toxicity was found in 100% of patients. Sixteen per cent
experienced a grade 3 skin reaction with no grade 4 events.
Forty-seven per cent experienced grade 3 diarrhea with only
1 patient having grade 4 diarrhea.
The overall response rate was 47% with an additional
5 patients (26%) with stable disease. The disease control rate
(DCR = OR + SD) was noted to be 74%. The median PFS
and OS were 5.6 months and 17 months respectively.
Twenty-four patients were enrolled into the expanded
portion of the study, evaluating panitumumab in combination
with FOLFIRI. As previously noted in earlier trial, FOLFIRI
was better tolerated with fewer patients experiencing grade
3 and grade 4 diarrhea (25% and 0%, respectively). 100%
of the patients experienced skin-related toxicity with grade
3 reactions in 17% and no grade 4 reactions.
The response rates were very similar to the earlier
portion of the study, with the DCR of 79% and median PFS
of 10.9 months. OS data have not been reported yet. This
has ultimately led to a randomized trial of FOLFIRI with or
without panitumumab, which is currently underway.

Panitumumab in combination
with cytotoxic chemotherapy
or biologic agents

Van Cutsem et al’s multicenter, randomized phase III
registration trial for panitumumab included a population of
heavily pretreated patients with metastatic CRC.33 A total of
463 patients with 1% EGFR-expressing tumors, measurable disease with radiological evidence of disease progression
during or within 6 months of their most recent chemotherapy

With other EGFR inhibitors, there has been a suggestion
of synergy or an additive effect with chemotherapy.10
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were enrolled. They were randomized to receive either
6 mg/kg of panitumumab every 2 weeks plus best supportive
care (n = 231) or best supportive care (BSC) alone (n = 232).
Assessment of treatment response was performed at 8 week
intervals and patients continued on treatment until disease
progression or intolerable toxicity was noted. The primary
endpoint was progression-free survival. Secondary endpoints
included objective response, overall survival and safety.
Patients randomized to BSC alone were allowed to crossover
to receive BSC with panitumumab if they were noted to have
disease progression. Panitumumab was found to significantly
prolong PFS (P  0.0001). At 8 weeks, 49% and 30% of
patients in the panitumumab and BSC groups, respectively,
has no evidence of progression.
Objective response rates also favored panitumumab
plus BSC arm (10%) over BSC alone (0%; p  0.0001). The
median time to response was 7.9 weeks and median duration
of response was 17.0 weeks. Stable disease was noted in
64 (28%) and 24 (10%) of patients in the panitumumab and
the BSC arms, respectively (results summarized in Table 1).
No difference in overall survival was noted, however this was
most likely due to the large number of patients in the BSC
arm that were allowed to crossover to receive panitumumab
on disease progression. In a subgroup analysis, there was a
correlation with skin reactions (grade 2 and 3 skin toxicity)
and prolonged PFS and OS. Other common toxicities
included hypomagnesemia, paronychia, fatigue, abdominal
pain, nausea and diarrhea. The most severe toxicities included
pulmonary fibrosis, severe dermatologic toxicity complicated
by sepsis and death and infusion reactions.
Thus, panitumumab in combination with BSC was found
to have antitumor activity in patients who had received
multiple previous chemotherapy agents. Results are comparable to those reported with single-agent cetuximab in the
same setting.10 Although response rates are only 10%, more
than a third of the patients had significant clinical benefit

with minimal toxicity. The trial design also allowed for
crossover to include addition of panitumumab to BSC. This
likely explains the lack of statistical difference in overall
survival between the two arms. Thus, panitumumab was
granted FDA approval in September 2006 for the treatment of
patients with EGFR-expressing, metastatic CRC with disease
progression on or following fluoropyrimidine-, oxaliplatin-,
and irinotecan-containing chemotherapy regimens.
More recently, the role of panitumumab was investigated
in combination with both cytotoxic chemotherapy and biologic agent, bevacizumab. The PACCE trial (Panitumumab
Advanced Colorectal Cancer Evaluation) was a randomized,
open-label, multicenter phase IIIB trial originally intended
to assess the efficacy and safety of bevacizumab plus
FOLFOX4 or FOLFIRI (doses and schedules determined by
investigators), with or without panitumumab, in the first-line
setting.34 In March 2007, a pre-planned interim analysis of
the first 231 events revealed that there was a statistically
significant difference in progression-free survival (PFS)
in favor of the control arm (without panitumumab). PFS
was significantly worse in the panitumumab arm of the
oxaliplatin-based chemotherapy (HR, 1.44; 95% CI, 1.13 to
1.85; P = 0.004). Median PFS time was 8.8 months (95% CI,
8.3 to 9.5 months) for panitumumab and 10.5 months (95%
CI, 9.4 to 12.0 months) for the control arm.
For the irinotecan-based chemotherapy cohort, median
PFS was 10.1 months for panitumumab and 11.9 months for
the control arm (HR, 1.57; 95% CI, 0.71 to 3.46). Toxicities, notably diarrhea, infections and pulmonary embolism
were also increased in the panitumumab arm. Thus, Amgen
decided to discontinue the panitumumab treatment arm in the
PACCE trial.34,35 The exact mechanism is currently unknown
but a few hypotheses suggested by the authors included pharmacokinetic interactions as well as increase in toxicity due to
dual-pathway inhibition in combination with chemotherapy.
Increased toxicity may have lead to more dose reductions,

Table 1 Summary of phase III registration trial results comparing best supportive care with panitumumab monotherapy in patients with
previously treated metastatic colorectal cancer, having failed irinotecan- and oxaliplatin-based therapy
Panitumumab arm
(n = 232)

Best supportive care
(n = 231)

PFS at 24 weeks (%)

18%

5%

PFS at 32 weeks (%)

10%

4%

RR (%)

8%

0%

Stable disease (%)

28%

10%

Disease control rate (%)

36%

10%

Median duration of response (weeks)

17 weeks

N/A

Abbreviations: PFS, progression-free survival; RR, response rate.
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treatment delays, decreases in dose intensity resulting in the
inferior results in the panitumumab arms.
A potential pharmacodynamic interaction induced by
EGFR inhibition may have also led to a blunting of the therapeutic effects of bevacizumab and/or chemotherapy.34

Ongoing studies
Currently, a number of phase I–III trials are evaluating
panitumumab in combination with cytotoxic chemotherapy
and/or biologic agents. For current trials, refer to Table 2.

Toxicity profile
The toxicity profile of panitumumab has been found to be
both favorable as well as highly predictable when evaluated
with pooled data in two safety analyses.36,37 Most common
toxicities included acneiform rash (all grades 53% to 4%;
Grade 3 and 4, 2% to 6%), pruritus (all grades 52% to 53%),
erythema (all grades 52% to 54%), paronychia (all grades
20%), fatigue (all grades 33% to 34%, grade 3 and 4, 6%),
nausea (all grades 29% to 30%, grade 3 and 4, 2%), diarrhea (all grades 26% to 27%, grade 3 and 4, 3%), abdominal
pain (all grades 21%, grade 3 and 4, 5%), hypomagnesemia
with clinical symptoms (all grades 5% to 6%, grade 3
and 4, 1% to 2%), hypomagenesemia without clinical symptoms (all grades 38% to 44%, grade 3 and 4, 5% to 6%).
The general incidence of treatment-related adverse events
experienced with panitumumab included 93% to 94% any
grade, 18% grade 3 and 1% grade 4. No deaths have been
reported that have been attributed to panitumumab. Three
per cent to 4% of patients did discontinue therapy due to
adverse toxicities.

Biomarkers of response
Even though EGFR inhibitors do demonstrate antitumor
activity in CRC and are well tolerated, there are still a
significant portion of patients who do not respond to these
therapies or have intolerable toxicities. With the ongoing
interest in personalizing cancer care, the shift has been to
identify markers of response as well as toxicity.
Skin toxicity with grade 3 or grade 4 rash has been
demonstrated to be a clinical marker of response. The underlying rationale for this has yet to be determined. It does not
appear to correlate with EGFR expression in tumor cells
(evaluated by immunohistochemistry). In a subset analysis
of Van Cutsem et al’s phase III trial of panitumumab vs best
supportive care, correlation was noted with severity of rash
and longer OS and PFS as well as improved quality-of-life
measures.38,39 There has also been some suggestion that skin
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toxicity may be a proposed surrogate marker for response to
cetuximab therapy10,40 and that dose escalation of cetuximab
aimed at increasing severity of skin rash may indeed increase
response rate. However, the overall effect was modest with
no statistically significant impact on disease control rates.41
Expression of EGFR itself has previously been
demonstrated to have no impact on response or clinical
benefit.10,40,42–45 Other markers of response to anti-EGFR
therapy have been investigated including EGFR gene
amplification and/or expression, EGFR mutations as well
as KRAS mutations. Most of the studies were performed in
non-small cell lung cancer; however, KRAS mutations have
been reported to be relatively common in sporadic CRC (30%
to 50% incidence).46–51 Several previous studies have identified the presence of mutated KRAS in lung and CRC tumors,
correlating with poorer prognosis50–54 and is also associated
with lack of response to anti-EGFR therapy.48,49,55–58 Up to
90% of activating mutations of the RAS gene are detected
on codons 12 and 13, but less frequently also in codon 61
and 63. In CRC, majority of the mutations (70%) occur in
codon 12, with 30% occurring in codon 13.59 Mutations of
the KRAS gene may activate downstream signal transduction
leading to resistance to upstream inhibition of the EGFR by
monoclonal antibodies.
Amado et al evaluated KRAS mutational status on patients
treated in a randomized, trial evaluating panitumumab vs
best supportive care.60 KRAS mutational status was obtained
on 427 (92%) of 463 patients (208 panitumumab arm, 219
BSC). KRAS mutations were detected by polymerase chain
reaction on DNA from tumor sections. KRAS mutations were
identified in 43% of patients. The results of the analysis
identified that the treatment effect on PFS on the wild-type
(WT) KRAS group (HR, 0.45; 95% CI, 0.34 to 0.59) was
significantly greater (P  0.0001) than in the mutant group
(HR, 0.99: 95% CI, 0.73 to 1.36). The median PFS in the
WT KRAS group was 12.3 weeks for panitumumab and 7.3
weeks for BSC. Reponse rates to panitumumab were 17%
and 0% for the WT and mutant groups respectively. WT
KRAS patients also had longer overall survival (HR, 0.67;
95% CI, 0.55 to 0.82). No significant differences in toxicity
were noted between the two groups.
The same effect of KRAS mutational status has also
been reported with cetuximab therapy.56,61 On the basis of
these results, the European Union drug regulatory body, the
European Medicines Agency, has approved panitumumab
only for metastatic CRC patients whose tumors display only
wild-type KRAS (Table 3). Currently, ASCO (American
Society of Clinical Oncology) also recommends following
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148

68

200

39

1269

Open label

Open-label, dose-finding,
phase Ib [AMG 706 plus
panitumumab + FOLFIRI or
FOLFOX4 chemotherapy]
Open-label

Multi-center, randomized, open
label, parallel assignment

Non-randomized

Randomized, open-label, active
control

Panitumumab DDI irinotecan

Safety of AMG 706 plus
panitumumab plus
chemotherapy in the treatment
of subjects with mCRC

Panitumumab and Irinotecan as third-line therapy in
treating patients with mCRC
[with WT KRAS in third line
chemotherapy] – patients previously treated with FOLFOX or
XELOX with or without bevacizumab and irinotecan alone
or FOLFIRI or CAPIRI with or
without bevacizumab

SPIRITT – q2w FOLFIRI
regimen plus panitumumab
or a q2w FOLFIRI regimen
plus bevacizumab for
2nd-line mCRC

Irinotecan and panitumumab
as 3rd line treatment for mCRC
without KRAS mutations

Irinotecan with or without
panitumumab or cyclosporine in
treating patients with advanced
or mCRC that did not respond
to fluorouracil

132

Randomized Phase Ib/2

Target accrual

Panitumumab combination
study with AMG 102 or AMG
479 in WT KRAS mCRC

Study design

Proportion of patients treated with
irinotecan hydrochloride (Ir) alone
vs Ir and cyclosporine (IrC) who are
progression-free at 12 weeks. Overall
survival of patients treated with Irv s Ir and
panitumumab (IrP) and no prior cetuximab

Response rate

Objective response rate

Objective response rate

Part 1 – evaluating for DLTs Part 2 –
Overall objective tumor response rate

cMax and AUC of irinotecan with and
without concomitant panitumumab administration

Phase I – safety Phase 2 – objective
response

Primary objective/s

December 2006

November
2008

November
2006

January 2008

December 2004

January 2008

November
2008

Start date

United Kingdom

Denmark

United States

France

United States
Australia

United States
Canada

United States
Belgium, Spain

Locations/
countries

Abbreviations: WT, wild-type; AUC, area under curve; mCRC, metastatic colorectal cancer; FOLFIRI, 5-fluorouracil, leucovorin, irinotecan; FOLFOX, 5-fluorouracil, leucovorin, oxaliplatin; DLT, dose limiting toxicity; XELOX, capecitabine,
oxaliplatin; CAPIRI, capecitabine, irinotecan; q2w, every 2 weeks.

Phase III

Phase II

Phase I

Study title

Table 2 Summary of ongoing clinical trials with panitumumab worldwide
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394 (572)
Karapetis61

Abbreviations: WT, wild-type; ORR, overall response rate; PFS, progression-free survival; mCRC, metastatic colorectal cancer; FOLFIRI, fluorouracil, leucovorin, irinotecan; C, cetuximab; FOLFOX, fluorouracil, leucovorin, oxaliplatin; Cap,
capecitabine; Oxal, oxaliplatin; B, bevacizumab; BSC, best supportive care; wks, weeks.

3.7 1.9
1.2 0
12.8 0
Cetuximab BSC
164/394 (41.6%)

12.3 wks
7.3 wks
00
17 0
Panitumumab BSC
184/427 (43%)
243/427 (56.9%)
427 (463)
Amado60

Second-line or salvage setting in mCRC

314/520 (60.3%)
775 (520)
Punt
[CAIRO2 trial]70

230/394 (58.3%)

7.4 wks
7.3 wks

8.1 12.5
(p = 0.003)
10.5 10.6
(p = 0.30)
61.4 50.0
(p = 0.06)
206/520 (39.6%)

Cap/Oxal/B + C Cap/Oxal/B

45.9 59.2
(p = 0.03)

5.5 8.6
(p = 0.019)
7.7 7.2
(p = 0.016)
61 37
(p = 0.011)
337 (233)
Bokemeyer
[OPUS trial]69

134/233 (58)

99/233 (42)

FOLFOX + C FOLFOX

36 40
59 43
(p = 0.0025)
1198 (540)
van Cutsem
[CRYSTAL trial]68

348/540 (64.4)

192/540 (35.6)

FOLFIRI + C FOLFIRI

WT
Mutant, n (%)
WT, n (%)
First-line setting in mCRC

33 49

9.9 8.7
(p = 0.017)

7.6 8.1

Mutant
WT
Mutant

PFS (months)
ORR (%)
Treatment
KRAS status (%)

Accrual
(# tumor assessed)
Author

Table 3 Summary of pivotal randomized clinical trials evaluating KRAS mutational status and impact on ORR and PFS in patients with mCRC treated with epidermal growth factor
receptor inhibitors

these guidelines; however, the FDA has held off on making
similar recommendations.
Santini et al recently reported high level of concordance
in the KRAS status of metastatic lesions and primary tumors.
In the metastatic setting, selecting therapy based on KRAS
mutational status is becoming more widely accepted.62
However, in the adjuvant setting, this is still under clinical
investigation. If both the primary tumor and metastatic
lesions share common characteristics such as KRAS mutational status, we could propose selecting therapies in the
adjuvant setting based on primary tumor characteristics, may
ultimately improve outcomes and reduce toxicity and cost.
Although this has changed the face of EGFR-inhibitor
therapy in CRC, only 30% to 50% of patient have KRAS
mutations, thus leaving a large proportion of patients that do
not respond to EGFR inhibitors despite having WT KRAS.
Di Nicolantonia et al proposed that in the absence of KRAS
mutations, resistance to EGFR inhibitors may be mediated by
alterations in the RAS-RAF-MAPK pathway.63 BRAF mutations occur in CRC in approximately 10%.64 BRAF mutations
have been linked to microsatellite instability, a condition
generally associated with better prognosis and resistance to
standard chemotherapy.65 Thus, KRAS mutational status as
well as microsatellite instability were evaluated in this trial.
Patients were selected based on evidence that treatment outcome could be attributed only to administration of cetuximab
or panitumumab. All patients had 1% tumor cells expressing EGFR assessed by immunohistochemistry. Once again,
KRAS was noted in approximately 30% of patients and was
associated with resistance to cetuximab or panitumumab
(P = 0.011). The BRAF V600E mutation was detected in
11 of 79 patients with WT KRAS. None of the BRAF-mutated
patients responded to treatment. None of the responders
carried BRAF mutations (P = 0.029). BRAF mutations in
patients led to a significantly shorter PFS (P = 0.011) and OS
(P  0.0001) than patients with WT BRAF. Thus, patients
whose tumors bear the BRAF V600E allele are unlikely
to benefit from EGFR inhibitor therapy. This could be an
additional tool for the selection of mCRC patients who may
benefit from EGFR-targeted therapies.
The PI3K/Akt signaling pathway is involved in cell
growth, resistance to apoptosis, invasion and migration.
PTEN (the lipid phosphatase and tensin homolog) is a key
tumor suppressor that normally regulates the activation of
PI3K.66 The loss of PTEN and mutations in PI3K have been
proposed to predict resistance to EGFR inhibitors, however, this is preliminary and no definite conclusions can be
derived.64
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Conclusions
We are entering an exciting era in the treatment of colorectal
cancer. Many advances have been made in the last few
years, specifically the addition of targeted therapies in the
treatment of mCRC. However, as we learn more about the
agents as well as their mechanism of action, we are able to
better target our treatment population. With the focus on
developing personalized cancer care, the shift has been to
tailor the treatment not only to the patient but also to tumor
biology. It has become imperative to identify molecular and
genetic mechanisms underlying responsiveness to monoclonal antibodies. This would allow us to select drugs for
patients based on the tumor’s molecular signature, improving
responses and outcomes, and avoiding unnecessary toxicities.
By selecting drugs for responsive patients, we would also
minimize the financial burden on the current healthcare
system.64 In targeting the EGFR pathway, panitumumab has
been shown to be well tolerated and effective in the treatment
of metastatic colorectal cancer. However, panitumumab only
be considered should in patients with wild-type KRAS.67
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